These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
    Author: Sánchez-Borges M, Bernstein DI, Calabria C.
    Journal: Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119.
    Abstract:
    Subcutaneous immunotherapy (SCIT) is effective for allergic rhinitis and conjunctivitis, asthma, and insect venom hypersensitivity. The risk of severe allergic reactions induced by SCIT remains low, and mild systemic reactions have recently shown a tendency to decline. However, near-fatal and fatal anaphylactic reactions may occur. Clinicians administering allergen-specific immunotherapy should receive specialized training and be aware of risk factors and preventive measures to avoid severe allergic reactions induced by SCIT.
    [Abstract] [Full Text] [Related] [New Search]